Aprea Therapeutics expands IP portfolio for precision oncology programs
Aprea Therapeutics announced an expansion of its intellectual property portfolio for precision oncology programs.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.